Sharemaestro company-news research for Stryker Corporation (S1YK34), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.

SAO Brazil Provisional evidence

Company news sentiment

Latest S1YK34 news and sentiment

Stryker Corporation

Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.

30-day score51Neutral is 50
Early balanced news score 22/100 evidence confidence 82% direct company focus 19 current stories across 4 publishers
Latest weekly closeBRL 71.11week of 18 Sep 2026
Main news subjectMarket update69/100 share of current news
News data statusPartial16 duplicate stories removed

Current company news

Early balanced news score

19 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.

Observed headline tone59/100 Published 30-day score51/100

Older, less relevant and less reliable stories count for less. Confidence is shown separately.

Latest source headline Stryker Facing Promising Setup Next Year, Trading Upside Limited in 2026, RBC Says finance.yahoo.com ยท 17 Sep 2026 15:14

What supports the score

Direct evidence

19 current stories are mapped specifically to S1YK34.

Source breadth

The score uses 4 publishers rather than depending on one outlet.

What limits the score

Too little evidence

The stories agree, but freshness-weighted evidence is only 0.157.

Confidence

Confidence is 22/100, below the threshold for a firm score.

51/100
News scoreEarly balanced news score
22/100
Confidencethin evidence
82%/100
Company news19 company stories
92/100
Story agreement8/100 difference

News history

Daily score and story count over 30 days

Daily weighted evidence
27 Aug: 1 stories31 Aug: 2 stories01 Sep: 4 stories03 Sep: 1 stories04 Sep: 2 stories08 Sep: 1 stories09 Sep: 2 stories10 Sep: 1 stories14 Sep: 2 stories15 Sep: 1 stories17 Sep: 2 stories 27 Aug: tone 50, 1 stories31 Aug: tone 50, 2 stories01 Sep: tone 50, 4 stories03 Sep: tone 50, 1 stories04 Sep: tone 50, 2 stories08 Sep: tone 44, 1 stories09 Sep: tone 55, 2 stories10 Sep: tone 38, 1 stories14 Sep: tone 55, 2 stories15 Sep: tone 46, 1 stories17 Sep: tone 63, 2 stories 95505
23 Aug07 Sep21 Sep
News scoreStory count50 baseline

Confidence

How reliable the score is

Separate from direction

Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.

Amount of evidence3
0.157 after freshness weighting
Source breadth80
4 independent publishers
Company relevance82
share tied directly to this company
Freshness28
recency-weighted evidence
Agreement92
how closely stories agree
Publisher mix52
less reliance on one publisher

Price and news history

Weekly price and news-score history

Early company-news score

Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.

26 completed price weeks13 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
27 Mar 2026: close 86.067284, indexed 100.003 Apr 2026: close 86.220001, indexed 100.210 Apr 2026: close 86.0, indexed 99.917 Apr 2026: close 85.519997, indexed 99.424 Apr 2026: close 82.0, indexed 95.301 May 2026: close 78.010796, indexed 90.608 May 2026: close 70.643936, indexed 82.115 May 2026: close 77.63147, indexed 90.222 May 2026: close 80.246803, indexed 93.229 May 2026: close 77.891006, indexed 90.505 Jun 2026: close 79.038956, indexed 91.812 Jun 2026: close 79.068901, indexed 91.919 Jun 2026: close 77.691368, indexed 90.326 Jun 2026: close 85.048233, indexed 98.803 Jul 2026: close 85.0, indexed 98.810 Jul 2026: close 83.940002, indexed 97.517 Jul 2026: close 79.5, indexed 92.424 Jul 2026: close 80.370003, indexed 93.431 Jul 2026: close 88.120003, indexed 102.407 Aug 2026: close 86.419998, indexed 100.414 Aug 2026: close 88.739998, indexed 103.121 Aug 2026: close 85.32, indexed 99.128 Aug 2026: close 84.970001, indexed 98.704 Sep 2026: close 79.269997, indexed 92.111 Sep 2026: close 70.739998, indexed 82.218 Sep 2026: close 71.110001, indexed 82.6 26 Jun 2026: news score 50, close 85.048233, 3 stories5003 Jul 2026: news score 50, close 85.0, 5 stories10 Jul 2026: news score 50, close 83.940002, 5 stories5017 Jul 2026: news score 50, close 79.5, 6 stories24 Jul 2026: news score 50, close 80.370003, 5 stories5031 Jul 2026: news score 47, close 88.120003, 15 stories07 Aug 2026: news score 55, close 86.419998, 22 stories5514 Aug 2026: news score 57, close 88.739998, 28 stories21 Aug 2026: news score 57, close 85.32, 31 stories5728 Aug 2026: news score 54, close 84.970001, 28 stories04 Sep 2026: news score 52, close 79.269997, 22 stories5211 Sep 2026: news score 52, close 70.739998, 26 stories18 Sep 2026: news score 52, close 71.110001, 25 stories52 Price index 105.6 92.6 79.6 News score 100 50 0
27 Mar23 Jun18 Sep
Weekly close, indexedSentiment score
26-week price-17.4%latest close 71.11
News score change+2first to latest comparable week
One-week response+0.5%Price digesting
Fair-value position-23.4%Below fair value
WeekNews scoreCloseWeekly move
18 Sep 202652BRL 71.110001+0.5%
11 Sep 202652BRL 70.739998-10.8%
04 Sep 202652BRL 79.269997-6.7%
28 Aug 202654BRL 84.970001-0.4%
21 Aug 202657BRL 85.32-3.9%
14 Aug 202657BRL 88.739998+2.7%
07 Aug 202655BRL 86.419998-1.9%
31 Jul 202647BRL 88.120003+9.6%
Provisional evidence

News subjects

What is shaping the score

Market update
Market update475 stories ยท 26%
Regulatory and legal484 stories ยท 21%
Deals and strategy504 stories ยท 21%
Analyst action613 stories ยท 16%
Earnings583 stories ยท 16%

Source mix

Where the evidence comes from

52/100 independence
finance.yahoo.com596 stories ยท 32%
MedTech Dive382 stories ยท 11%
MT Newswires612 stories ยท 11%
Simply Wall St.472 stories ยท 11%
GlobeNewswire502 stories ยท 11%
Zacks502 stories ยท 11%
Investing.com441 stories ยท 5%

Recurring subjects

Subjects appearing most often

Current evidence
Healthcare7Fda Approval6Earnings4M A3Earnings Per Share3Earnings Growth3Augmented Reality3Sports Medicine2Medical Technology2Intrinsic Value2

Earlier readings

How the score has changed

35 comparable readings ยท 91 days
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
Comparable move+150 to 51 ยท Broadly stable
Observed range47โ€“5750 is the neutral baseline
Evidence depth21stories at latest stored reading ยท +20
Confidence18/100Provisional ยท +18
22 Jun50 neutral21 Sep 13:11
ConstructiveBalanced or withheldCautious

Changes in the stored score

Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.

ObservedScoreMoveConfidenceStoriesStatus
21 Sep 13:1151-118/100 (-8)21 (-5)Provisional
17 Sep 23:5952+126/100 (+4)26 (+2)Provisional
15 Sep 23:5951+022/100 (-3)24 (+1)Provisional
14 Sep 23:5951-125/100 (-5)23 (-3)Provisional
10 Sep 23:5952-130/100 (-1)26 (0)Provisional
09 Sep 23:5953+231/100 (+7)26 (+4)Provisional
08 Sep 23:5951-124/100 (+5)22 (0)Provisional
04 Sep 23:5952+019/100 (0)22 (+1)Provisional

Source headlines

The news behind the score

Showing 1-19 of 19

Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.

#161Tone
finance.yahoo.comDirect company coverageStored article

Stryker Facing Promising Setup Next Year, Trading Upside Limited in 2026, RBC Says

Stryker (SYK) will likely see an acceleration story in 2027, with high single digit growth achievabl PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in

Published
17 Sep 2026 15:14
News subject
Analyst action
Why this score
Positive financial language
Company focus
Shared story ยท 78%
How it is used
Direct company coverage
Story strength
Medium ยท 41/100
30-day weight
19.7% of the score ยท 3.9d old
Duplicates
1 consolidated
#264Tone
finance.yahoo.comDirect company coverageStored article

Stryker Expands Foot & Ankle Innovation With Prophecy and smartHEX

Stryker SYK recently announced the expansion of its Foot & Ankle portfolio with the launch of Prophecy Surgical Planning for the Incompass Total Ankle System and the introduction of Hoffmann LRF smartHEX at the 2026 American Orthopedic Foot & Ankle Society (AOFAS) Annual Meeting. The new additions are designed to advance patient-specific surgical planning, implant flexibility and connected care across ankle replacement and limb reconstruction procedures. Management highlighted that strong customer adoption and positive feedback for Prophecy have encouraged Stryker to expand the platform to the

EarningsEarnings GrowthEarnings Per ShareFda ApprovalFoot And AnkleMedical Devices
Published
17 Sep 2026 15:00
News subject
Earnings
Why this score
Business expansion
Company focus
Shared story ยท 78%
How it is used
Direct company coverage
Story strength
Medium ยท 50/100
30-day weight
45% of the score ยท 3.9d old
Duplicates
2 consolidated
#3Not directional
Simply Wall St.Direct company coverageStored article

Stryker (SYK) Stock Still Looks Cheap On Its 24% Slide

Stryker has seen its share price slide sharply over the past year, and the question now is whether the current valuation still lines up with the cash the business is expected to generate. For investors watching the stock after recent headlines, the focus has shifted from past returns to whether today's price fairly reflects those underlying cash flows. The stock has fallen 24.5% over the past year, which puts the spotlight on whether that move has brought the valuation closer to what its future cash flows can support. Ongoing manufacturing issues in the peripheral vascular business and the rel

Cash FlowEarningsFree Cash FlowFuture Cash FlowsIntrinsic ValueSecurities Investigation
Published
15 Sep 2026 15:17
News subject
Regulatory and legal
Why this score
Negative market reaction
Company focus
Shared story ยท 78%
How it is used
Shown as company news ยท not used in the score
Story strength
Not directional
30-day weight
None ยท 5.9d old
Duplicates
1 consolidated
#4Not directional
TrefisDirect company coverageScored from headline

Why Pay More For Stryker When BSX Stock Is On Sale?

Published
14 Sep 2026 18:16
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company ยท 100%
How it is used
Shown as company news ยท not used in the score
Story strength
Not directional
30-day weight
None ยท 6.8d old
Duplicates
1 consolidated
#557Tone
MT NewswiresDirect company coverageScored from headline

Bernstein Adjusts Price Target on Stryker to $385 From $420, Keeps Outperform Rating

Published
14 Sep 2026 11:47
News subject
Analyst action
Why this score
Positive financial language
Company focus
Main company ยท 100%
How it is used
Direct company coverage
Story strength
Low ยท 34/100
30-day weight
11.4% of the score ยท 7.1d old
Duplicates
1 consolidated
#638Tone
MedTech DiveDirect company coverageScored from headline

Stryker stock falls on slower peripheral vascular, hip sales

Published
10 Sep 2026 12:06
News subject
Market update
Why this score
Negative market reaction
Company focus
Main company ยท 100%
How it is used
Direct company coverage
Story strength
Low ยท 35/100
30-day weight
1.4% of the score ยท 11.0d old
Duplicates
1 consolidated
#768Tone
MT NewswiresDirect company coverageScored from headline

Citigroup Adjusts Stryker Price Target to $360 From $399, Maintains Buy Rating

Published
09 Sep 2026 13:45
News subject
Analyst action
Why this score
Buy Rating
Company focus
Main company ยท 100%
How it is used
Direct company coverage
Story strength
Medium ยท 42/100
30-day weight
5.7% of the score ยท 12.0d old
Duplicates
1 consolidated
#8Not directional
finance.yahoo.comDirect company coverageStored article

Pulmera Appoints Jared Slibeck Chief Commercial Officer

Twenty-year industry veteran in surgical navigation and enabling technology joins Pulmera to spearhead commercial adoption of its CBeamโ„ข 3D Imaging Platform, the first C-Arm Native 3D imaging system. 20-Year Stryker Veteran Jared Slibeck Joins Pulmera as Chief Commercial OfficerJared Slibeck has been named Chief Commercial Officer for Pulmera, effective September 1, 2026. Slibeck will lead the company's commercial strategy and market development as the company brings the CBeamโ„ข 3D Imaging Platform into hospitals and surgery centers across the country. Slibeck joins Pulmera after more than twen

Fda ApprovalHealthcareImagingMedical TechnologySurgery
Published
09 Sep 2026 12:58
News subject
Regulatory and legal
Why this score
The headline reports news without a clear direction
Company focus
Company discussed ยท 86%
How it is used
Shown as company news ยท not used in the score
Story strength
Not directional
30-day weight
None ยท 12.0d old
Duplicates
1 consolidated
#944Tone
Investing.comDirect company coverageStored article

Supply chain woes send Stryker stock tumbling 7.7%

Investing.com -- Stryker Corp. shares dropped as much as 7.7% on Tuesday morning after company executives discussed ongoing problems in its peripheral vascular and joint replacement operations at an industry conference. The company presented at the Wells Fargo Healthcare Conference, where Chief Financial Officer Preston Wells addressed issues affecting the business. Wells explained that a manufacturing problem continues to prevent the company from maintaining full inventory supply to customers. The issue also limits the company's ability to pursue new business opportunities. The company had ex

Fourth QuarterHealthcareManufacturingSupply Chain
Published
08 Sep 2026 15:31
News subject
Earnings
Why this score
Negative market reaction, Large negative market reaction
Company focus
Shared story ยท 78%
How it is used
Direct company coverage
Story strength
Low ยท 34/100
30-day weight
16.9% of the score ยท 12.9d old
Duplicates
1 consolidated
#10Not directional
GlobeNewswireDirect company coverageStored article

Schedule update: Stryker to participate in the 2026 Wells Fargo Healthcare Conference

Stryker Corporation Portage, Michigan, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2026 Wells Fargo Healthcare Conference on Tuesday, September 8, 2026, at the Encore Boston Harbor, as previously reported. Preston Wells, Vice President, Chief Financial Officer and Nick Mead, Vice President, Investor Relations will now participate in a fireside chat session at 10:15 a.m. (Eastern time). A simultaneous live audio webcast and replay of the session can be accessed at Stryker - Events & Presentations. About Stryker Stryker is a global leader in medical technologies

Healthcare
Published
04 Sep 2026 22:32
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Shared story ยท 78%
How it is used
Shown as company news ยท not used in the score
Story strength
Not directional
30-day weight
None ยท 16.6d old
Duplicates
1 consolidated
#11Not directional
Insider MonkeyDirect company coverageStored article

Stryker (SYK) is Buying ZuriMED. Can FiberLocker Strengthen its Shoulder Portfolio?

Stryker Corporation (NYSE:SYK) signed a definitive agreement to acquire privately held ZuriMED, which would add the commercialized FiberLocker System to its shoulder portfolio upon closing. FiberLocker is designed to reinforce rotator-cuff repairs by strengthening the connection between a surgical patch and tendon tissue. The transaction remains subject to customary closing conditions, while the purchase price and expected financial contribution were not disclosed. The strategic logic is straightforward. Stryker Corporation (NYSE:SYK) can place FiberLocker alongside its existing sports-medicin

AcquisitionFda ApprovalHealthcareM A
Published
04 Sep 2026 18:36
News subject
Deals and strategy
Why this score
The headline reports news without a clear direction
Company focus
Shared story ยท 78%
How it is used
Shown as company news ยท not used in the score
Story strength
Not directional
30-day weight
None ยท 16.8d old
Duplicates
1 consolidated
#12Not directional
ZacksDirect company coverageStored article

Stryker Launches FDA-Cleared Apple Vision Pro Surgical App

Stryker SYK recently announced the successful completion of the first hip arthroscopy procedure using its SportSuite Vision application on Apple Vision Pro at Duke Health. The milestone follows the FDA's De Novo authorization for the application in July, making it the first surgical application approved for intraoperative use with Apple's mixed reality headset. From an investor's perspective, the development reinforces Stryker's push to strengthen its digital surgery portfolio and expand innovation across its Sports Medicine business. Although the launch is unlikely to materially affect near-t

AcquisitionAugmented RealityDigital SurgeryEarnings GrowthEarnings Per ShareFda Approval
Published
03 Sep 2026 17:37
News subject
Deals and strategy
Why this score
The headline reports news without a clear direction
Company focus
Shared story ยท 78%
How it is used
Shown as company news ยท not used in the score
Story strength
Not directional
30-day weight
None ยท 17.8d old
Duplicates
1 consolidated
#13Not directional
Simply Wall St.Direct company coverageStored article

Stryker (SYK) Wins FDA Nod And Completes First Procedure With New Surgery Software

Stryker (NYSE:SYK) received FDA De Novo authorization for its SportSuite Vision software on Apple Vision Pro in a clinical setting. The company reported completion of the first surgical procedure using SportSuite Vision in an operating room environment. The software introduces augmented reality and spatial computing tools into surgical workflows and operating room visualization. The authorization marks a regulatory milestone for Stryker in mixed reality applications for healthcare. This move into augmented reality and spatial computing is part of a wider shift across medical technology and AI

Augmented RealityDigital HealthFda ApprovalHealthcareQuarterly ResultsSurgical Technologies
Published
01 Sep 2026 17:06
News subject
Regulatory and legal
Why this score
The headline reports news without a clear direction
Company focus
Shared story ยท 78%
How it is used
Shown as company news ยท not used in the score
Story strength
Not directional
30-day weight
None ยท 19.8d old
Duplicates
1 consolidated
#14Not directional
MedTech DiveDirect company coverageScored from headline

Stryker to add rotator cuff repair tech with ZuriMED buy

Published
01 Sep 2026 17:02
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company ยท 100%
How it is used
Shown as company news ยท not used in the score
Story strength
Not directional
30-day weight
None ยท 19.8d old
Duplicates
1 consolidated
#15Not directional
ZacksDirect company coverageStored article

Stryker to Acquire ZuriMED to Expand Its Shoulder Care Portfolio

Stryker SYK recently announced a definitive agreement to acquire ZuriMED, developer of the FiberLocker System, a commercialized technology designed for rotator cuff augmentation with increased biomechanical strength. The acquisition is aimed at strengthening Stryker's shoulder portfolio and expanding its ability to support specialists across the continuum of shoulder care. Per Stryker management, ZuriMED's technology addresses an important unmet need for shoulder care. The addition of the FiberLocker System is expected to complement Stryker's existing offerings while reinforcing its focus on a

EarningsEarnings GrowthEarnings Per ShareHealthcareM ASports Medicine
Published
01 Sep 2026 14:10
News subject
Deals and strategy
Why this score
The headline reports news without a clear direction
Company focus
Shared story ยท 78%
How it is used
Shown as company news ยท not used in the score
Story strength
Not directional
30-day weight
None ยท 20.0d old
Duplicates
1 consolidated
#16Not directional
finance.yahoo.comDirect company coverageStored article

Stryker introduces first of its kind FDA-authorized surgical application for Apple Vision Pro with hip arthroscopy case at nationally recognized academic medical center

SportSuite Vision brings spatial computing into the operating room, providing surgeons access to critical clinical information Stryker announced the successful completion of the first surgical procedure, a hip arthroscopy, using SportSuite Vision on Apple Vision Pro at a leading academic medical center. Stryker received FDA De Novo authorization for the first surgical application for intraoperative use with Apple Vision Pro, SportSuite Vision. SportSuite Vision brings arthroscopic video, HipCheck, HipMap and CT imaging into a customizable spatial computing environment, helping surgeons access

Augmented RealityFda ApprovalMedical TechnologySurgical Procedures
Published
01 Sep 2026 13:05
News subject
Regulatory and legal
Why this score
The headline reports news without a clear direction
Company focus
Shared story ยท 78%
How it is used
Shown as company news ยท not used in the score
Story strength
Not directional
30-day weight
None ยท 20.0d old
Duplicates
1 consolidated
#17Not directional
finance.yahoo.comDirect company coverageStored article

Stryker (SYK) Stock Looks Like A Bargain Near Fair Value

Stryker stock has delivered a modest total return over the past five years, while the current intrinsic value estimate from a Discounted Cash Flow (DCF) framework suggests the shares trade at a discount to that internal calculation. At the same time, market based valuation multiples point to pricing that is broadly in line with peers, which leaves investors weighing two different valuation signals. Stryker has returned about 23.3% over the past five years, which points to a measured long term outcome rather than a runaway winner or a clear disappointment. The company's ability to grow cash flo

Discounted Cash FlowEarningsFree Cash FlowFuture Cash FlowsIntrinsic ValueMedical Equipment
Published
31 Aug 2026 23:06
News subject
Earnings
Why this score
The headline reports news without a clear direction
Company focus
Shared story ยท 78%
How it is used
Shown as company news ยท not used in the score
Story strength
Not directional
30-day weight
None ยท 20.6d old
Duplicates
1 consolidated
#18Not directional
finance.yahoo.comDirect company coverageStored article

Stryker signs definitive agreement to acquire ZuriMED to enhance its shoulder offering

Stryker Corporation Portage, Mich., USA, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Stryker has signed a definitive agreement to acquire ZuriMED, developer of the FiberLocker System, a commercialized technology that provides a novel approach for rotator cuff augmentation designed for increased biomechanical strength. The acquisition strengthens Stryker's shoulder portfolio, enhancing its ability to support specialists across the continuum of care. The FiberLocker System is a soft tissue augmentation technology designed to reduce the occurrence of a key clinical failure mode in rotator cuff repair, one

M AMedical TechnologiesSports Medicine
Published
31 Aug 2026 20:05
News subject
Deals and strategy
Why this score
The headline reports news without a clear direction
Company focus
Shared story ยท 78%
How it is used
Shown as company news ยท not used in the score
Story strength
Not directional
30-day weight
None ยท 20.7d old
Duplicates
1 consolidated
#19Not directional
GlobeNewswireDirect company coverageStored article

Stryker to participate in the 2026 Wells Fargo Healthcare Conference

Stryker Corporation Portage, Michigan, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2026 Wells Fargo Healthcare Conference on Tuesday, September 8, 2026, at the Encore Boston Harbor. Preston Wells, Vice President, Chief Financial Officer and Nick Mead, Vice President, Investor Relations will also participate in a fireside chat session at 2:15 p.m. (Eastern time). A simultaneous live audio webcast and replay of the session can be accessed at Stryker - Events & Presentations. About Stryker Stryker is a global leader in medical technologies and, together with our c

ConferenceHealthcareMedtech
Published
27 Aug 2026 19:00
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Shared story ยท 78%
How it is used
Shown as company news ยท not used in the score
Story strength
Not directional
30-day weight
None ยท 24.8d old
Duplicates
1 consolidated

Earlier company news

S1YK34 news archive

Showing 1-30 of 37 stored headlines

Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.

Sep 16 2026
finance.yahoo.comArchivedNeutral tone

Stryker showcases Foot & Ankle innovation at AOFAS 2026 with Prophecyยฎ Surgical Planning for Incompassโ„ข and Hoffmannยฎ LRF smartHEXโ„ข

New additions advance surgical planning, implant flexibility and connected care across Stryker's Foot & Ankle portfolio Stryker is launching Prophecyยฎ Surgical Planning for the Incompassโ„ข Total Ankle System and introducing HoffmannยฎLRF smartHEXโ„ข at the 2026 American Orthopaedic Foot & Ankle Society Annual Meeting in Seattle. Prophecyยฎ Surgical Planning, which has supported patient-specific planning for more than 100,000 ankle cases over 14 years, is now available with the Incompassโ„ข Total Ankle System, giving surgeons access to 3D visualization and both resect-through and pin-through fixation

Medical DevicesOrthopaedicsSurgical Planning
Published
16 Sep 2026 14:06
Catalyst
Market update
Coverage
Direct company
Duplicates
1 consolidated
Aug 21 2026
finance.yahoo.comArchivedNeutral tone

US$100 Million Defense Contract Win Might Change The Case For Investing In Stryker (SYK)

Stryker's sales unit in Michigan previously secured a US$100.00 million contract modification from the U.S. Defense Logistics Agency, underscoring its role as a key supplier to government healthcare and logistics systems. This award highlights the importance of stable government contracting as a complement to Stryker's hospital and surgical product revenue mix. We'll now examine how this sizable Defense Logistics Agency contract influences Stryker's investment narrative, particularly its government-linked revenue visibility. Rare earth metals are the new gold rush. Find out which 28 stocks are

DividendsFair ValueGovernment ContractsMedical TechnologyReimbursementRevenue Growth
Published
21 Aug 2026 17:11
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Aug 21 2026
finance.yahoo.comArchivedNeutral tone

Here's Why You Should Hold Stryker Stock in Your Portfolio for Now

Stryker SYK entered 2026 facing an unexpected cyber disruption, yet underlying demand, robotics adoption and international momentum remained strong. While a robust capital pipeline and active acquisition strategy support long-term growth, execution risks tied to recovery efforts, margin pressures and expanding exposure to new markets could shape the company's performance over the coming quarters. This Zacks Rank #3 (Hold) company's shares have lost 6.7% so far this year compared with the industry's 15.2% decline. The S&P 500 Index has appreciated 11.2% in the same time frame. Stryker is a glob

Published
21 Aug 2026 16:12
Catalyst
Macro sensitivity
Coverage
Direct company
Duplicates
1 consolidated
Aug 21 2026
finance.yahoo.comArchivedPositive tone

Stryker (SYK) Wins $100 Million Contract, Is It Still Below Fair Value?

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Stryker (SYK) is back in focus after its Stryker Sales unit secured a $100 million contract modification from the US Defense Logistics Agency, a development that coincided with a 2.7% share price move. See our latest analysis for Stryker. For context, Stryker's share price has been volatile around recent news, with a 4.17% 1 month share price return and a 5.88% decline year to date, while the 1 year total shareholder return is down 13.98%, the 3 year total shareholder return

ContractHealthcareInnovationShare PriceShareholderValuation
Published
21 Aug 2026 12:11
Catalyst
Deals and strategy
Coverage
Direct company
Duplicates
1 consolidated
Aug 20 2026
finance.yahoo.comArchivedPositive tone

Are Wall Street Analysts Predicting Stryker Stock Will Climb or Sink?

Doctor scientist looking at test tube solution by MIND AND I via Adobe Stock Valued at a market cap of $127.1 billion, Stryker Corporation (SYK) is a global medical technology company that develops and sells a broad range of products designed to improve surgical procedures and patient outcomes. The Michigan-based company's portfolio spans MedSurg and Neurotechnology, including surgical equipment, endoscopy systems, patient-handling solutions, emergency-care products, neurovascular devices, and neurosurgical technologies, as well as Orthopaedics, covering joint replacement implants, trauma and

Consensus EstimateEarningsEarnings SurpriseGuidanceMedical DevicesMedtech
Published
20 Aug 2026 12:20
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Aug 19 2026
finance.yahoo.comArchivedPositive tone

Why Stryker (SYK) Stock Is Trading Up Today

Why Stryker (SYK) Stock Is Trading Up Today What Happened? Shares of medical technology company Stryker (NYSE:SYK) jumped 2.7% in the afternoon session after its Stryker Sales unit in Michigan won a $100 million contract modification from the US Defense Logistics Agency. The U.S. Department of Defense announced the award, as reported by MarketScreener. This development likely boosted investor confidence in the company's revenue stream from government contracts. The shares closed the day at $340.05, up 2.6% from the previous close. Is now the time to buy Stryker? Access our full analysis report

Defense ContractsEarningsGuidanceRevenue GrowthShare Price
Published
19 Aug 2026 23:54
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Aug 14 2026
finance.yahoo.comArchivedPositive tone

What Does Stryker (SYK) Q1 Growth Mean If Costs Are Still Pressuring Earnings?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Stryker (NYSE:SYK) reported strong first quarter growth, supported by underlying demand and a recovery from a prior cyber incident. The company highlighted organic growth across its main divisions that was driven by customer volume rather than acquisitions. A wide gap between reported and adjusted earnings raised questions about ongoing costs that are weighing on profitability. For readers interested in other income focused healthcare ideas, the next logical step is to explore 11

CybersecurityDividendsEarningsFree Cash FlowHealthcareMedical Technology
Published
14 Aug 2026 20:08
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Aug 14 2026
finance.yahoo.comArchivedPositive tone

Can Stryker (SYK) Still Look Undervalued After Backlog Recovery?

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Stryker stock has delivered a 35.9% gain over the past five years, yet current checks suggest it is not an obvious bargain, even as an Intrinsic Value estimate using a Discounted Cash Flow (DCF) framework points to the shares trading below that intrinsic value by 19.8%. Stryker's 35.9% return over five years indicates the stock has rewarded long term holders. New investors now need to weigh valuation more carefully than during earlier stages of the move. Strong demand for Str

Discounted Cash FlowFree Cash FlowFuture Cash FlowsIntrinsic ValueMedical EquipmentShare Price
Published
14 Aug 2026 04:16
Catalyst
Balance sheet
Coverage
Direct company
Duplicates
1 consolidated
Aug 13 2026
finance.yahoo.comArchivedPositive tone

Can Stryker's Q2 Recovery and Guidance Support a Stronger Second Half?

Stryker Corporation SYK entered the second half of 2026 with momentum restored after the March cybersecurity disruption. Second-quarter sales, earnings and margins improved as production recovered, while management narrowed its full-year outlook. The next test is execution. Stryker must keep normalizing production, convert elevated backlog into shipments and support a broad product launch cycle. Those factors will determine whether the stronger second half embedded in management's expectations materializes. Stryker's Q2 Recovery Rebuilt Momentum Stryker reported second-quarter net sales of $6.

CybersecurityEarningsGuidanceMakoMedical Devices
Published
13 Aug 2026 18:49
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Aug 13 2026
finance.yahoo.comArchivedPositive tone

Stryker Up 13.6% in 3 Months as Recovery Gains Strength, What's Next?

Stryker Corporation SYK shares have risen 13.6% in the past three months, outpacing the Zacks Medical sector's 12.9% gain and the S&P 500's 1.7% advance. The move has coincided with a sharper operating recovery after a difficult first quarter. The investor question is whether improving sales, margins and production can keep supporting the stock, or whether execution demands and a richer relative valuation now make the next leg higher harder to achieve.Zacks Investment Research Image Source: Zacks Investment Research Why Stryker's Three-Month Rally Has Support Stryker's second-quarter results g

EarningsEarnings GrowthHealthcareMedical
Published
13 Aug 2026 18:49
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Aug 13 2026
finance.yahoo.comArchivedNeutral tone

Wolfe Research downgrades Stryker, upgrades Abbott in med-tech shuffle

Investing.com -- Wolfe Research made two rating changes across large-cap medical devices, downgrading Stryker while upgrading Abbott Laboratories on Thursday. Analyst Mike Polark cut Stryker to Peer Perform, citing a demanding second-half setup following the company's March cyber disruption. He said the June quarter "wasn't a huge catch up thus year not yet de-risked," leaving "a higher-than-normal burden on 2H to deliver." As a result, Wolfe sees the near-term skew to estimates "leans negative," with growth "more likely to slow to 8% vs speed up to 10% in 2027." The firm flagged that Stryker'

Medical DevicesPrice TargetUpgrade Downgrade
Published
13 Aug 2026 13:37
Catalyst
Analyst action
Coverage
Direct company
Duplicates
1 consolidated
Aug 11 2026
finance.yahoo.comArchivedNeutral tone

Strykerโ€™s (SYK) Comeback Quarter Looks Great, But At What Cost?

Stryker (NYSE:SYK) turned in one of its stronger quarters in recent memory on July 30, with sales climbing 9.4% to $6.6 billion and reported EPS jumping 44.1% to $3.30. The numbers arrive as the company works its way back from a cyber incident that had rattled its business, and CEO Kevin Lobo pointed to that recovery as proof of the company's resilience. But a closer look at how those earnings were adjusted tells a more complicated story about what is really driving the bottom line.Stryker's (SYK) Comeback Quarter Looks Great, But At What Cost? Bull Case: Growth That Touched Every Corner Of Th

EarningsEarnings Per ShareGuidanceMedical DevicesOperating Income
Published
11 Aug 2026 22:23
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Aug 05 2026
finance.yahoo.comArchivedPositive tone

Stryker declares an $0.88 per share quarterly dividend

Stryker Corporation Portage, Michigan, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable October 30, 2026, to shareholders of record at the close of business on September 30, 2026, representing an increase of 4.8% versus the prior year and unchanged from the previous quarter. About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopa

Dividends
Published
5 Aug 2026 14:34
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Aug 02 2026
finance.yahoo.comArchivedNeutral tone

Solventum (SOLV) Appoints Neil Zieselman As New Chief Accounting Officer

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Solventum (NYSE:SOLV) has appointed Neil Zieselman as Senior Vice President, Controller, and Chief Accounting Officer. He will succeed current Controller and Chief Accounting Officer Mary Wilcox following her retirement. Zieselman brings experience from Surgery Partners Inc., Stryker Corporation, Covanta Holding Corporation, Cendant Corporation, and Avaya Inc., and is a licensed CPA. Solventum enters this leadership change w

Financial ReportingLeadership ChangeStock Performance
Published
2 Aug 2026 15:08
Catalyst
Market update
Coverage
Direct company
Duplicates
1 consolidated
Aug 02 2026
finance.yahoo.comArchivedPositive tone

Is Stryker (SYK) Undervalued As Earnings Trigger A Fresh Valuation Question?

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Stryker (SYK) is back in focus after its second quarter 2026 earnings, reporting sales of US$6.59b and net income of US$1.28b, alongside a sharp market reaction to the release. See our latest analysis for Stryker. The 1 day share price return of Stryker fell 6.42% on the earnings release, which pulled the year to date share price return down 6.46%, while the 5 year total shareholder return of 30.66% still reflects longer term gains. If Stryker's move has y

EarningsEarnings GrowthEarnings ReleaseHealthcareNet IncomePrice Target
Published
2 Aug 2026 02:11
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Aug 01 2026
finance.yahoo.comArchivedPositive tone

How Strong Q2 Earnings, Raised Guidance and Cyber Recovery Will Impact Stryker (SYK) Investors

Stryker Corporation's recently reported Q2 2026 results showed sales rising to US$6,589 million and net income to US$1,276 million, with both basic and diluted EPS from continuing operations increasing compared with the prior year period. Management also highlighted 9% organic sales growth, recovery progress after a March cyberattack that disrupted operations, and a slight increase to full-year adjusted EPS guidance while planning to resume share repurchases. We will now examine how this combination of strong earnings, raised guidance, and post-cyberattack recovery shapes Stryker's broader inv

EarningsGuidanceHealthcareNet IncomeRoboticsShare Buyback
Published
1 Aug 2026 17:12
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Aug 01 2026
finance.yahoo.comArchivedPositive tone

SYK Q2 Deep Dive: Supply Chain Disruptions Weigh on Growth Outlook Despite Margin Expansion

SYK Q2 Deep Dive: Supply Chain Disruptions Weigh on Growth Outlook Despite Margin Expansion Medical technology company Stryker (NYSE:SYK) met Wall Street's revenue expectations in Q2 CY2026, with sales up 9.4% year on year to $6.59 billion. Its non-GAAP profit of $3.69 per share was 5.8% above analysts' consensus estimates. Is now the time to buy SYK? Find out in our full research report (it's free). Stryker (SYK) Q2 CY2026 Highlights: Revenue: $6.59 billion vs analyst estimates of $6.57 billion (9.4% year-on-year growth, in line) Adjusted EPS: $3.69 vs analyst estimates of $3.49 (5.8% beat) M

CybersecurityEarningsFree Cash FlowGuidanceMedical TechnologyRevenue Growth
Published
1 Aug 2026 04:31
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Jul 31 2026
finance.yahoo.comArchivedNeutral tone

Why Stryker (SYK) Shares Are Plunging Today

Why Stryker (SYK) Shares Are Plunging Today What Happened? Shares of medical technology company Stryker (NYSE:SYK) fell 7.3% in the morning session after the company reported second-quarter results that showed revenue that only met Wall Street's expectations and organic sales growth that missed forecasts. While the company reported a solid 9.4% year-on-year increase in revenue to $6.59 billion, investors were likely expecting a stronger performance. The 9% organic revenue growth, a key measure of core business health that strips out acquisitions and currency effects, fell short of expectations

EarningsGuidanceMedical TechnologyPrice TargetRevenue GrowthShare Price
Published
31 Jul 2026 16:23
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Jul 31 2026
finance.yahoo.comArchivedNegative tone

Stryker nets $6.6bn revenue in Q2; highlights resilience following cyberattack

Stryker has reported Q2 revenues of $6.6bn, denoting a 9.4% rise year-over-year (YoY), with the company's CEO lauding its "significant progress" in recovering since its global operations were disrupted by an cyberattack in March. Following the results, Stryker is tweaking its 2026 outlook at the low end, with earnings now projected to land in the $14.95 to $15.10 per share range, up from $14.90 to $15.10 previously. Stryker's orthopaedic segment revenues totalled almost $3bn, representing a YoY uptick of 9.2%. Meanwhile the majority of proceeds for the quarter came from the company's medsurg a

CybersecurityEarningsEarnings Per ShareGuidanceMedtechSplit
Published
31 Jul 2026 12:23
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Jul 31 2026
finance.yahoo.comArchivedPositive tone

Stryker Corp (SYK) (Q2 2026) Earnings Call Highlights: Strong 9% Organic Growth and Raised ...

This article first appeared on GuruFocus. Organic Sales Growth: 9% for Q2 2026, against a double-digit comparable in Q2 2025. Adjusted EPS: $3.69, up 17.9% year-over-year. Adjusted Gross Margin: 66%, 60 basis points favorable to Q2 2025. Adjusted Operating Margin: 27.4% of sales, 170 basis points favorable to Q2 2025. Adjusted Effective Tax Rate: 16.5% for Q2 2026. Cash and Marketable Securities: Approximately $3.5 billion at end of Q2. Year-to-Date Cash from Operations: $1.8 billion. MedSurg and Neurotechnology Organic Sales Growth: 9.2% (US: 8.9%, International: 10.5%). Orthopaedics Organic

Balance SheetDividendsEarningsEarnings Per ShareFourth QuarterGuidance
Published
31 Jul 2026 06:04
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Jul 31 2026
seekingalpha.comArchivedPositive tone

Stryker expects 8.3%-9.3% organic sales growth and $14.95-$15.10 adjusted EPS in 2026 as it resumes share repurchases

Earnings Call Insights: Stryker (SYK) Q2 2026 MANAGEMENT VIEW * CEO Kevin Lobo said, "Our second quarter results demonstrated the strength of our broad product portfolio and resiliency of our teams," and added, "Our recovery from the cybersecurity incident continued as we ramped overall production to meet ongoing demand and support patient care." * Lobo highlighted the operational setback in Peripheral Vascular and the expected timing of normalization: "the supply disruption resulted in a meaningful back order situation with lost sales in the quarter. We have addressed the issue and back order

CybersecurityEarningsEarnings Per ShareFourth QuarterGuidanceRevenue Growth
Published
31 Jul 2026 02:36
Catalyst
Macro sensitivity
Coverage
Direct company
Duplicates
1 consolidated
Jul 30 2026
finance.yahoo.comArchivedNeutral tone

Stryker (SYK) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

For the quarter ended June 2026, Stryker (SYK) reported revenue of $6.59 billion, up 9.4% over the same period last year. EPS came in at $3.69, compared to $3.13 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $6.56 billion, representing a surprise of +0.48%. The company delivered an EPS surprise of +6.65%, with the consensus EPS estimate being $3.46. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate pictur

EarningsMedsurgNeurotechnologyOrthopaedicsRevenue
Published
30 Jul 2026 23:00
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Jul 30 2026
finance.yahoo.comArchivedNegative tone

Stryker (NYSE:SYK) Posts Q2 CY2026 Sales In Line With Estimates But Stock Drops

Stryker (NYSE:SYK) Posts Q2 CY2026 Sales In Line With Estimates But Stock Drops Medical technology company Stryker (NYSE:SYK) met Wall Street's revenue expectations in Q2 CY2026, with sales up 9.4% year on year to $6.59 billion. Its non-GAAP profit of $3.69 per share was 5.8% above analysts' consensus estimates. Is now the time to buy Stryker? Find out in our full research report. Stryker (SYK) Q2 CY2026 Highlights: Revenue: $6.59 billion vs analyst estimates of $6.57 billion (9.4% year-on-year growth, in line) Adjusted EPS: $3.69 vs analyst estimates of $3.49 (5.8% beat) Management slightly r

EarningsEarnings Per ShareGrowth RateGuidanceHealthcareMedical Devices
Published
30 Jul 2026 21:30
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Jul 30 2026
globenewswire.comArchivedNeutral tone

Stryker reports second quarter 2026 operating results

Portage, Michigan, July 30, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the second quarter of 2026: Second Quarter Results Reported net sales increased9.4% to $6.6 billionOrganic net sales increased9.0%Reported operating income margin of 25.2%Adjusted operating income margin(1)increased170 bps to27.4%Reported EPS increased44.1% to $3.30Adjusted EPS(1)increased17.9% to $3.69 Second Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Neurotechnology 9.7 % 0.5 % 9.2 % โ€” % 9.2 %Orthopae

EarningsEarnings Per ShareEarnings Releases And Operating ResultsFinancial ResultsGuidanceMedtech
Published
30 Jul 2026 21:05
Catalyst
Earnings
Coverage
Direct company
Duplicates
2 consolidated
Jul 28 2026
finance.yahoo.comArchivedNeutral tone

Stryker (SYK) Launches Mako RPS To Bring Robotic Knee Surgery To More Surgeons

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Stryker has introduced Mako RPS, a robotic handheld system for total knee replacement, expanding its Mako robotics portfolio. The launch extends robotic assistance to a wider range of orthopaedic procedures and care settings. The development highlights Stryker's focus on robotic-assisted surgery and surgeon flexibility in knee replacement. Stryker, traded as NYSE:SYK, is drawing attention with the launch of Mako RPS alongside a share price of $336.74. The stock is up 5.5% ove

HealthcareOrthopaedicsRoboticsShare Price
Published
28 Jul 2026 15:07
Catalyst
Market update
Coverage
Direct company
Duplicates
1 consolidated
Jul 27 2026
finance.yahoo.comArchivedNeutral tone

PAHC vs. SYK: Which Stock Is the Better Value Option?

Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Stryker (SYK). But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identif

EarningsEarnings EstimateEarnings GrowthEstimate RevisionsMedical ProductsShare Price
Published
27 Jul 2026 16:40
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated

Provider matches checked

Provider mentions not used in the score

4 not scored

A news provider linked these stories to S1YK34, but the headline and available text are not mainly about Stryker Corporation. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.

Provider mentions are kept separate

Open the list to see which provider matches were checked and left out of S1YK34 sentiment.

Open provider mentions

How the page works

How to read the score

The score shows direction

It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.

Confidence is separate

Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.

Price is confirmation

Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.

What the page does

It measures news already published. It is not a forecast, recommendation or price target.

Evidence context